Better Therapeutics rises on FDA authorization for its diabetes treatment application

Better Therapeutics

11/07/2023 11:34

** Shares of prescription digital therapeutics co Better
Therapeutics Inc  BTTX.O  rise 48.89% to $1.34 premarket, among
top pct. gainers across U.S. exchanges
    ** Co late on Monday said U.S. FDA authorized its
prescription-only digital therapeutic application AspyreRx
    ** The app is indicated to provide cognitive behavioral
therapy to patients 18 years or older with type 2 diabetes
    ** AspyreRx is expected to launch commercially in Q4 2023
    ** Type 2 diabetes is a chronic condition that affects the
way the body processes blood sugar
    ** Up to last close, stock down ~19% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))